Unibest

Pharmaceutical intermediates

Pazopanib Hydrochloride Intermediates

4 pharmaceutical intermediates for Pazopanib Hydrochloride. Indication: Renal cell carcinoma; Sarcoma; Soft tissue sarcoma.

提交项目All intermediates

About Pazopanib Hydrochloride

Originator
Novartis Pharmaceuticals Corp
Indication
Renal cell carcinoma; Sarcoma; Soft tissue sarcoma
Approved Date
10/19/2009

Available intermediates

4 intermediates currently listed for Pazopanib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Pazopanib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Methyl-6-nitroindazole6494-19-5//
2,3-Dimethyl-2H-indazol-6-amine hydrochloride635702-60-2/1444731-72-0//
N-(2-chloropyrimidin-4-yl)-N,2,3-trimethyl-2H-indazol-6-amine444731-75-3//
3-Amino-6-methylbenzenesulfonamide9/7/6973//

Other programs under P

PacritinibPalbociclibParecoxib sodiumParicalcitolPaxlovidPeficitinib HydrobromidePemafibratePeramivir

Building toward Pazopanib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →